A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential

Bing Zhou, Longfa Xu, Rui Zhu, Jixian Tang, Yangtao Wu, Ruopeng Su, Zhichao Yin, Dongxiao Liu, Yichao Jiang, Can Wen, Min You, Linlin Dai, Yu Lin, Yuanzhi Chen, Haijie Yang, Zhiqiang An, Changfa Fan, Tong Cheng, Wenxin Luo, Ningshao Xia

Research output: Contribution to journalArticle

Abstract

Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the major pathogens of hand, foot and mouth disease (HFMD), which affects children worldwide and is often associated with neurological complications. At present, there is no vaccine or cure available for simultaneous EV71 and CA16 infection, posing a great need to develop novel strategies for the treatment of this disease. Here, we engineered four bispecific antibodies using variable fragments of monoclonal antibodies (mAbs) from EV71- and CA16-specific neutralizing antibodies. The engineered bispecific antibody Bs(scFv)4-IgG-1 exhibits remarkable cross-reactivity against EV71 and CA16 and has a more potent cross-neutralization than its parental antibodies. Furthermore, we showed that Bs(scFv)4-IgG-1 conferred 100% therapeutic efficacy against single or mixed EV71 and CA16 infections in mice. Our study provides important insights into bispecific antibody engineering against enterovirus and will inform new curative treatment options for HFMD.

LanguageEnglish
Pages28-35
Number of pages8
JournalAntiviral Research
Volume161
DOIs
StatePublished - Jan 1 2019

Fingerprint

Bispecific Antibodies
Enterovirus
Neutralizing Antibodies
Hand, Foot and Mouth Disease
Coxsackievirus Infections
Therapeutics
Immunoglobulin G
Vaccines
Monoclonal Antibodies

Keywords

  • Bispecific antibody
  • Conformation
  • Coxsackievirus A16
  • Enterovirus 71
  • Neutralizing activity

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. / Zhou, Bing; Xu, Longfa; Zhu, Rui; Tang, Jixian; Wu, Yangtao; Su, Ruopeng; Yin, Zhichao; Liu, Dongxiao; Jiang, Yichao; Wen, Can; You, Min; Dai, Linlin; Lin, Yu; Chen, Yuanzhi; Yang, Haijie; An, Zhiqiang; Fan, Changfa; Cheng, Tong; Luo, Wenxin; Xia, Ningshao.

In: Antiviral Research, Vol. 161, 01.01.2019, p. 28-35.

Research output: Contribution to journalArticle

Zhou, B, Xu, L, Zhu, R, Tang, J, Wu, Y, Su, R, Yin, Z, Liu, D, Jiang, Y, Wen, C, You, M, Dai, L, Lin, Y, Chen, Y, Yang, H, An, Z, Fan, C, Cheng, T, Luo, W & Xia, N 2019, 'A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential' Antiviral Research, vol. 161, pp. 28-35. https://doi.org/10.1016/j.antiviral.2018.11.001
Zhou, Bing ; Xu, Longfa ; Zhu, Rui ; Tang, Jixian ; Wu, Yangtao ; Su, Ruopeng ; Yin, Zhichao ; Liu, Dongxiao ; Jiang, Yichao ; Wen, Can ; You, Min ; Dai, Linlin ; Lin, Yu ; Chen, Yuanzhi ; Yang, Haijie ; An, Zhiqiang ; Fan, Changfa ; Cheng, Tong ; Luo, Wenxin ; Xia, Ningshao. / A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. In: Antiviral Research. 2019 ; Vol. 161. pp. 28-35.
@article{cf853a2214b441cbb270bc790f804434,
title = "A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential",
abstract = "Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the major pathogens of hand, foot and mouth disease (HFMD), which affects children worldwide and is often associated with neurological complications. At present, there is no vaccine or cure available for simultaneous EV71 and CA16 infection, posing a great need to develop novel strategies for the treatment of this disease. Here, we engineered four bispecific antibodies using variable fragments of monoclonal antibodies (mAbs) from EV71- and CA16-specific neutralizing antibodies. The engineered bispecific antibody Bs(scFv)4-IgG-1 exhibits remarkable cross-reactivity against EV71 and CA16 and has a more potent cross-neutralization than its parental antibodies. Furthermore, we showed that Bs(scFv)4-IgG-1 conferred 100{\%} therapeutic efficacy against single or mixed EV71 and CA16 infections in mice. Our study provides important insights into bispecific antibody engineering against enterovirus and will inform new curative treatment options for HFMD.",
keywords = "Bispecific antibody, Conformation, Coxsackievirus A16, Enterovirus 71, Neutralizing activity",
author = "Bing Zhou and Longfa Xu and Rui Zhu and Jixian Tang and Yangtao Wu and Ruopeng Su and Zhichao Yin and Dongxiao Liu and Yichao Jiang and Can Wen and Min You and Linlin Dai and Yu Lin and Yuanzhi Chen and Haijie Yang and Zhiqiang An and Changfa Fan and Tong Cheng and Wenxin Luo and Ningshao Xia",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.antiviral.2018.11.001",
language = "English",
volume = "161",
pages = "28--35",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential

AU - Zhou, Bing

AU - Xu, Longfa

AU - Zhu, Rui

AU - Tang, Jixian

AU - Wu, Yangtao

AU - Su, Ruopeng

AU - Yin, Zhichao

AU - Liu, Dongxiao

AU - Jiang, Yichao

AU - Wen, Can

AU - You, Min

AU - Dai, Linlin

AU - Lin, Yu

AU - Chen, Yuanzhi

AU - Yang, Haijie

AU - An, Zhiqiang

AU - Fan, Changfa

AU - Cheng, Tong

AU - Luo, Wenxin

AU - Xia, Ningshao

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the major pathogens of hand, foot and mouth disease (HFMD), which affects children worldwide and is often associated with neurological complications. At present, there is no vaccine or cure available for simultaneous EV71 and CA16 infection, posing a great need to develop novel strategies for the treatment of this disease. Here, we engineered four bispecific antibodies using variable fragments of monoclonal antibodies (mAbs) from EV71- and CA16-specific neutralizing antibodies. The engineered bispecific antibody Bs(scFv)4-IgG-1 exhibits remarkable cross-reactivity against EV71 and CA16 and has a more potent cross-neutralization than its parental antibodies. Furthermore, we showed that Bs(scFv)4-IgG-1 conferred 100% therapeutic efficacy against single or mixed EV71 and CA16 infections in mice. Our study provides important insights into bispecific antibody engineering against enterovirus and will inform new curative treatment options for HFMD.

AB - Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the major pathogens of hand, foot and mouth disease (HFMD), which affects children worldwide and is often associated with neurological complications. At present, there is no vaccine or cure available for simultaneous EV71 and CA16 infection, posing a great need to develop novel strategies for the treatment of this disease. Here, we engineered four bispecific antibodies using variable fragments of monoclonal antibodies (mAbs) from EV71- and CA16-specific neutralizing antibodies. The engineered bispecific antibody Bs(scFv)4-IgG-1 exhibits remarkable cross-reactivity against EV71 and CA16 and has a more potent cross-neutralization than its parental antibodies. Furthermore, we showed that Bs(scFv)4-IgG-1 conferred 100% therapeutic efficacy against single or mixed EV71 and CA16 infections in mice. Our study provides important insights into bispecific antibody engineering against enterovirus and will inform new curative treatment options for HFMD.

KW - Bispecific antibody

KW - Conformation

KW - Coxsackievirus A16

KW - Enterovirus 71

KW - Neutralizing activity

UR - http://www.scopus.com/inward/record.url?scp=85056638026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056638026&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2018.11.001

DO - 10.1016/j.antiviral.2018.11.001

M3 - Article

VL - 161

SP - 28

EP - 35

JO - Antiviral Research

T2 - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -